moxifloxacin has been researched along with Cardiotoxicity in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bobesh, KA; Kulkarni, P; Renuka, J; Srilakshmi, RR; Sriram, D; Yellanki, S; Yogeeswari, P | 1 |
| Aghasafari, P; Bekker, S; Clancy, CE; Dawson, JRD; DeMarco, KR; Jeng, MT; Noskov, SY; Vorobyov, I; Yang, PC; Yarov-Yarovoy, V | 1 |
| Berg, A; Hanna, D; Hermann, D; Jamei, M; Patel, N; Polak, S; Romero, K | 1 |
| Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V | 1 |
| Khalid, UK; Kumar Verma, A; Mathuria, KK; Munjal, S; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Vohra, V | 1 |
| Blinova, K; Daluwatte, C; Patel, D; Schocken, D; Strauss, DG; Vicente, J; Wu, JC | 1 |
1 trial(s) available for moxifloxacin and Cardiotoxicity
| Article | Year |
|---|---|
Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs.
Topics: Action Potentials; Adult; Cardiotoxicity; Cell Differentiation; Cells, Cultured; Cross-Over Studies; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Induced Pluripotent Stem Cells; Long QT Syndrome; Male; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Primary Cell Culture; Sulfonamides; Toxicity Tests | 2019 |
5 other study(ies) available for moxifloxacin and Cardiotoxicity
| Article | Year |
|---|---|
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Topics: Animals; Antitubercular Agents; Atrioventricular Block; Cardiotoxicity; DNA Gyrase; Enzyme Assays; Ether-A-Go-Go Potassium Channels; Heart Rate; Mycobacterium tuberculosis; Naphthyridines; Novobiocin; Piperazines; Terfenadine; Topoisomerase II Inhibitors; Zebrafish; Zebrafish Proteins | 2016 |
A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotoxicity; Cardiotoxins; Computer Simulation; Drug Discovery; ERG1 Potassium Channel; Female; Humans; Long QT Syndrome; Machine Learning; Male; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Protein Structure, Secondary; Sulfonamides; Topoisomerase II Inhibitors | 2020 |
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development.
Topics: Adult; Algorithms; Antitubercular Agents; Cardiotoxicity; Diarylquinolines; Drug Development; Electrocardiography; Female; Heart; Humans; Male; Moxifloxacin; Risk Assessment; Sensitivity and Specificity; Torsades de Pointes; Tuberculosis | 2018 |
Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Topics: Adult; Cardiotoxicity; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Imipenem; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Salvage Therapy; Sputum; Survival Rate; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Topics: Adult; Antitubercular Agents; Cardiotoxicity; Clofazimine; Cycloserine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Ethionamide; Female; Humans; India; Linezolid; Male; Moxifloxacin; National Health Programs; Sputum; Time Factors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |